1. Home
  2. CLOV vs RAPP Comparison

CLOV vs RAPP Comparison

Compare CLOV & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

HOLD

Current Price

$2.58

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc. Common Stock

HOLD

Current Price

$29.66

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLOV
RAPP
Founded
2014
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
CLOV
RAPP
Price
$2.58
$29.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$4.23
$46.60
AVG Volume (30 Days)
5.4M
377.9K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,773,564,000.00
N/A
Revenue This Year
$41.68
N/A
Revenue Next Year
$37.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.15
N/A
52 Week Low
$2.12
$6.43
52 Week High
$4.87
$42.27

Technical Indicators

Market Signals
Indicator
CLOV
RAPP
Relative Strength Index (RSI) 47.73 62.48
Support Level $2.41 $26.92
Resistance Level $2.72 $30.44
Average True Range (ATR) 0.12 1.80
MACD 0.04 0.20
Stochastic Oscillator 74.98 90.28

Price Performance

Historical Comparison
CLOV
RAPP

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: